Bret Weinstein: If you can predict the future….You can print money.

Also Bret: If would be great if we could convince your body to produce the product [insulin] itself, like a healthy person does.

Hey, do you hate how overeating and not exercising makes you fat and gives you that pesky disease diabetes???

Wouldn’t it be easier if you didn’t have do anything annoying, like modify your eating habits or lifestyle? Don’t you just wish you could like, inject something that would just fix the insulin issue in your pancreas???

Well I’ve got some great news…it sure is looking like there’s a bright future in store for you!

PROBLEM:

Every country in the world is expected to see rates increase 

SEATTLE, Wash. June 22, 2023 – More than half a billion people are living with diabetes worldwide, affecting men, women, and children of all ages in every country, and that number is projected to more than double to 1.3 billion people in the next 30 years, with every country seeing an increase, as published today in The Lancet(link is external).   
The study was funded by the Bill & Melinda Gates Foundation. 

Diabetes: Overview

Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or alternatively, when the body cannot effectively use the insulin it produces. The vast majority of Diabetes can be classified as either type 1 or type 2 diabetes. Type 1 diabetes is an autoimmune disease is characterized by a lack of insulin production by the pancreas. Type 2 diabetes occurs when body becomes resistant to insulin, and sugar builds up in the blood. About 90% of people with diabetes around the world have type 2. It is largely the result of excess body weight and physical inactivity. Diabetes can cause a heart attack, stroke, blindness, kidney disease, nerve damage, and other serious health problems.

SOLUTION:

PROBLEM:

Ozempic^® may cause serious side effects, including:

• inflammation of your pancreas (pancreatitis). Stop using Ozempic^® and call your health care provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.

SOLUTION:

About Rejuva

Fractyl Health’s Rejuva platform focuses on developing next-generation adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of T2D and obesity. The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. Rejuva leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas. The program aims to transform the management of metabolic diseases by offering novel, disease-modifying therapies that address the underlying root causes of disease

It’s going to be bigger and better than semaglutides(Ozempic)!

Conducting considerable experiments with animal models in previous, RosVivo has collected strong and compelling data for RSVI-301's efficacy compared to GLP-1 receptor agonist. GLP-1 receptor agonist is currently known as a game-changer to treat diabetes and obesity in the market. Eli Lilly will review and acknowledge the animal experiment data and ensure the potential of RSVI-301 through this MTA.

(GLP-1 = Ozempic, Wegovy, Mounjaro)

RosVivo Therapeutics, Inc. signed a Material Transfer Agreement (MTA) for first-in-class diabetes treatment with Eli Lilly and Company

Published: Feb 22, 2022

RSVI-301, a new drug candidate adopting miRNA technology, enters the technology export process.

RosVivo's RSVI-301 pipeline is the world's first in class new drug candidate that can fundamentally treat diabetes by restoring the function of beta cells that secrete insulin, the cause of diabetes, and at the same time lowering insulin resistance. Currently, diabetes is not fundamentally treated because diabetes drugs only temporarily lower blood sugar. In addition, RSVI-301 is considered an ideal next-generation new drug candidate for diabetes treatment with fewer side effects as it shows excellent therapeutic effects on obesity, fatty liver and digestive gastrointestinal disorders in animal testing. (source)

While the development of RNA vaccines has been spotlighted since the Corona-19 outbreak, RSVI-301, a new drug pipeline of RosVivo targeting diabetes, also uses miRNA (micro RNA). Consisting of 20–24 nucleotide, miRNA is known as a "small cleaner" in the body that naturally regulates metabolic processes of genes and proteins. Since these miRNA treatments inject human-derived genetic materials, they are expected to be of greater value in stability than conventional mRNA treatments using external genetic materials like viruses.

PROBLEM:

Eli Lilly warns against ‘cosmetic’ use of popular diabetes, obesity drugs

01/04/24

Drugmaker Eli Lilly on Thursday warned against using its diabetes and obesity drugs for “cosmetic” weight loss, as the medications have exploded in popularity, resulting in shortages. 

In an open letter posted online, the company said its products Mounjaro and Zepbound “are indicated for the treatment of serious diseases; they are not approved for — and should not be used for — cosmetic weight loss.“ 

SOLUTION:

Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs

Jan. 5, 2024

Novo Nordisk A/S NVO announced that it has entered into separate research collaborations with Omega Therapeutics OMGA and a privately-held biotech company, Cellarity, to develop novel treatment approaches for cardiometabolic diseases.

The collaboration deal with Omega Therapeutics will leverage the company’s proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as part of a potential new treatment approach for obesity management.

Novo Nordisk, Eli Lilly's obesity drugs will lead in new drug sales in 2024:

Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk and Eli Lilly—overwhelming the market with their dominance.

Expect more of the same in 2024, according to a recent report from Evaluate, which places Novo and Lilly in the top two spots for global new sales. The analysts peg Novo’s sales increase to approach $8 billion in 2024, while Lilly’s will come in at close to $5 billion.

Gosh, it really looks like this is a lucrative promising investment treatment for diabetes/obesity.

And it sounds like a gene therapy version will be even more lucrative helpful than the wildly overprescribed popular semaglutides!

Hey, do you remember the last gene therapy technology injection?

They were like, 100% sure that their injectable bioweapon was fucking awesome.

Oopsies!

Sometimes 17 million people have to die.

Let’s move on and stuff, I think I heard the future’s going to be brighter.

Pricking that finger will be a thing of the past!

Pricking your DNA will be waaaaay better!!!